drugset
drugset / Trial / NCT01981720

Extension Study of PRX-102 for up to 60 Months

NCT01981720 ↗

Phase 1/2 Completed 15 enrolled Protalix Chiesi Farmaceutici S.p.A. · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01 and PB-102-F02.

Timeline

Start
2014-01-16
Primary completion
2020-08-26
Completion
2021-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject pegunigalsidase alfa Protein / enzyme biologic 1 mg/kg Intravenous

Indications

Fabry disease